Bullfrog AI Holdings, Inc. Common Stock (BFRG) 10-K 29 Mar 24 2023 FY Annual report Financial data

Cover

Cover - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Mar. 27, 2024	Jun. 30, 2023
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2023
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-41600
Entity Registrant Name	BULLFROG AI HOLDINGS, INC.
Entity Central Index Key	0001829247
Entity Tax Identification Number	84-4786155
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	325 Ellington Blvd.
Entity Address, Address Line Two	Unit 317
Entity Address, City or Town	Gaithersburg
Entity Address, State or Province	MD
Entity Address, Postal Zip Code	20878
City Area Code	240
Local Phone Number	658-6710
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 11.7
Entity Common Stock, Shares Outstanding		7,850,550
Documents Incorporated by Reference [Text Block]	None
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Auditor Firm ID	2738
Auditor Name	M&K CPAS, PLLC
Auditor Location	Houston, Texas
Common Stock, Par Value $0.00001 Per Share [Member]
Title of 12(b) Security	Common Stock, par value $0.00001 per share
Trading Symbol	BFRG
Security Exchange Name	NASDAQ
Tradable Warrants [Member]
Title of 12(b) Security	Tradable Warrants
Trading Symbol	BFRGW
Security Exchange Name	NASDAQ

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 2,624,730	$ 57,670
Prepaid expenses	145,882	15,000
Total current assets	2,770,612	72,670
Property and equipment, net	5,974	7,699
Total assets	2,776,586	80,369
Current liabilities:
Accounts payable	103,656	543,993
Accrued expenses	80,694	982,988
Deferred revenue		32,000
Total current liabilities	184,350	3,137,721
Total liabilities	184,350	3,137,721
Stockholders’ equity (deficit):
Series A Convertible Preferred stock, $0.00001 par value, 5,500,000 shares  authorized; 73,449 shares issued and outstanding, as of December 31, 2023 and 2022.	1	1
Common stock, $0.00001 par value, 100,000,000 shares authorized; 6,094,644 and 4,021,935 shares issued and outstanding as of December 31, 2023 and 2022, respectively.	61	40
Additional paid-in capital	12,347,098	1,341,662
Accumulated deficit	(9,754,924)	(4,399,055)
Total stockholders’ equity (deficit)	2,592,236	(3,057,352)
Total liabilities and stockholders’ equity (deficit)	2,776,586	80,369
Nonrelated Party [Member]
Current liabilities:
Convertible notes		1,323,890
Related Party [Member]
Current liabilities:
Convertible notes		$ 254,850

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2023	Dec. 31, 2022
Preferred stock, par value	$ 0.00001
Preferred stock, shares authorized	10,000,000
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares, issued	6,094,644	4,021,935
Common stock, shares, outstanding	6,094,644	4,021,935
Series A Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	5,500,000	5,500,000
Preferred stock, shares issued	73,449	73,449
Preferred stock, shares outstanding	73,449	73,449

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue:
Revenue, net Revenue	$ 65,000	$ 10,000
Total revenue	65,000	10,000
Cost of goods sold:
Cost of goods sold	5,200	800
Total cost of goods sold	5,200	800
Gross profit	59,800	9,200
Operating expenses:
Research and development	1,432,614	609,270
General and administrative	3,994,710	1,855,731
Total operating expenses	5,427,324	2,465,001
Loss from operations	(5,367,524)	(2,455,801)
Other income (expense), net
Interest expense, net	(79,089)	(347,145)
Loss on conversion of notes	(92,959)
Interest income	183,703	459
Total other income (expense), net	11,655	(346,686)
Net loss	$ (5,355,869)	$ (2,802,487)
Net loss per common share attributable to common stockholders basic	$ (0.89)	$ (0.70)
Net loss per common share attributable to common stockholders diluted	$ (0.89)	$ (0.70)
Weighted average number of shares outstanding - basic	6,049,819	4,009,852
Weighted average number of shares outstanding - diluted	6,049,819	4,009,852

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)	Preferred Stock [Member] Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2021		$ 46	$ 587,415	$ (1,596,568)	$ (1,009,107)
Balance, shares at Dec. 31, 2021		4,622,789
Imputed interest			9,221		9,221
Stock-based compensation			340,152		340,152
Reclassification of warrant			(11,097)		(11,097)
Conversion of convertible debt to common stock		$ 2	226,136		226,138
Conversion of convertible debt to common stock, shares		205,984
Shares cancellation		$ (1)	1
Shares cancellation, shares		(112,225)
Issuance of common stock pursuant to warrant exercises			189,828		189,828
Issuance of common stock pursuant to warrant exercises, shares		39,879
Common stock converted to Series A Preferred Stock	$ 1	$ (7)	6
Common stocks converted to Series A Preferred stock, shares	73,449	(734,492)
Net loss				(2,802,487)	(2,802,487)
Balance at Dec. 31, 2022	$ 1	$ 40	1,341,662	(4,399,055)	(3,057,352)
Balance, shares at Dec. 31, 2022	73,449	4,021,935
Stock-based compensation			631,533		631,533
Conversion of convertible debt to common stock		$ 3	1,535,612		1,535,615
Conversion of convertible debt to common stock, shares		331,166
Issuance of common stock pursuant to warrant exercises		$ 4	1,494,654		1,494,658
Issuance of common stock pursuant to warrant exercises, shares		436,533
Net loss				(5,355,869)	(5,355,869)
Issuance of common stock (initial public offering), net of issuance costs		$ 13	7,293,638		7,293,651
Issuance of common stock (initial public offering), net of issuance cots, shares		1,297,318
Issuance of common stock for services		$ 1	49,999		50,000
Issuance of common stock for services, shares		7,692
Balance at Dec. 31, 2023	$ 1	$ 61	$ 12,347,098	$ (9,754,924)	$ 2,592,236
Balance, shares at Dec. 31, 2023	73,449	6,094,644

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net loss	$ (5,355,869)	$ (2,802,487)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	1,725	1,045
Stock-based compensation	631,533	340,152
Shares issued for license		189,828
Shares issued for services	50,000
Loss on conversion of notes	92,959
Amortization of debt discount	20,000	214,429
Imputed interest		9,221
Changes in operating assets and liabilities:
Prepaid expense	(130,882)	(15,000)
Accounts payable	(440,337)	475,399
Accrued expenses	(838,428)	373,273
Accrued expenses - related party		281,250
Deferred revenue	(32,000)	22,000
Net cash used in operating activities	(6,001,299)	(910,890)
Cash flows from investing activities:
Purchases of property and equipment		(8,744)
Net cash used in investing activities		(8,744)
Cash flows from financing activities:
Proceeds from issuance of common stock (initial public offering), net of issuance costs	7,293,651
Proceeds from exercise of warrants	1,494,658
Proceeds from convertible notes payable		1,016,290
Proceeds from notes payable	100,000
Payments of notes payable	(319,950)
Repayment of note payable and interest - related party		(49,000)
Proceeds from short term insurance financing	697,534
Payments of short term insurance financing	(697,534)
Net cash provided by financing activities	8,568,359	967,290
Net increase in cash and cash equivalents	2,567,060	47,656
Cash and cash equivalents, beginning of period	57,670	10,014
Cash and cash equivalents, end of period	2,624,730	57,670
Supplemental cash flow information:
Cash paid for interest	93,916	5,757
Cash paid for taxes
Supplemental non-cash activity
Reclassification of warrant		11,097
Issuance of common stock upon conversion of notes payable	1,535,615
Conversion of convertible note payable		226,138
Cancellation of common stock		$ 8

Organization and Nature of Busi

Organization and Nature of Business	12 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Nature of Business	1. Organization and Nature of Business Description of Business Bullfrog AI Holdings, Inc. (“we”, “our” or the “Company”) was incorporated in the State of Nevada on February 6, 2020. Bullfrog AI Holdings, Inc. is the parent company of Bullfrog AI, Inc. and Bullfrog AI Management, LLC which were incorporated in Delaware and Maryland, in 2017 and 2021, respectively. All of our operations are currently conducted through BullFrog AI Holdings, Inc., which began operations on February 6, 2020. We are a company focused specifically on advanced AI/ML-driven analysis of complex data sets in medicine and healthcare. Our objective is to utilize our platform for precision medicine approach to drug asset enablement through external partnerships and selective internal development. Most new therapeutics will fail at some point in preclinical or clinical development. This is the primary driver of the high cost of developing new therapeutics. A major part of the difficulty in developing new therapeutics is efficient integration of complex and highly dimensional data generated at each stage of development to de-risk subsequent stages of the development process. Artificial Intelligence and Machine Learning (AI/ML) has emerged as a digital solution to help address this problem. We use artificial intelligence and machine learning to advance medicines for both internal and external projects. Most current AI/ML platforms still fall short in their ability to synthesize disparate, high-dimensional data for actionable insight. Our platform technology, named, bfLEAP™ is an analytical AI/ML platform developed at The Johns Hopkins University Applied Physics Laboratory (JHU-APL) which is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise, multi-dimensional understanding of their data. We are deploying bfLEAP™ for use at several critical stages of development for internal programs and through strategic partnerships and collaborations with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may otherwise not receive the therapies they need. The bfLEAP™ platform utilizes both supervised and unsupervised machine learning – as such, it is able to reveal real/meaningful connections in the data without the need for a priori hypothesis. Algorithms used in the bfLEAP™ platform are designed to handle highly imbalanced data sets to successfully identify combinations of factors that are associated with outcomes of interest. Our primary goal is to improve the odds of success at any stage of pre-clinical and clinical therapeutics development, for in house programs, and our strategic partners and collaborators. Our primary business model is enabling the success of ongoing clinical trials or rescue of late stage failed drugs (i.e., Phase 2 or Phase 3 clinical trial failures) for development and divestiture; although, we will also consider collaborations for earlier stage drugs. We hope to accomplish this through strategic acquisitions of current clinical stage and failed drugs for in-house development, or through strategic partnerships with biopharmaceutical industry companies. We are able to pursue our drug asset enhancement business by leveraging a powerful and proven AI/ML platform (trade name: bfLEAP™) initially developed at JHU-APL. We believe the bfLEAP™ analytics platform is a potentially disruptive tool for analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational R&D and clinical trial settings. Liquidity and Going Concern The Company has had negative cash flows from operations and operated at a net loss since inception. In the first quarter of 2023, we completed our initial public offering (“IPO”). In February 2024 the Company received net proceeds of approximately $ 4.9 1,507,139 1,507,139 3.782 5 4.16 218,382 750,000

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying consolidated financial statements include the accounts of Bullfrog AI Holdings, Inc. and our wholly owned subsidiaries and have been prepared in conformity with United States generally accepted accounting principles (“GAAP”). All intercompany accounts and transactions have been eliminated in consolidation. On February 13, 2023, we completed a 1-for-7 reverse split of our common stock Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. These estimates include, but are not limited to, revenue recognition, allowances for doubtful accounts, recoverability of deferred tax assets and certain other of our accrued liabilities. Actual results could differ from these estimates. Revenue Recognition The Company recognizes revenue based on the following five step model: ● Identification of the contract with a customer This step outlines the criteria that must be met when establishing a contract with a customer to supply goods or services. ● Identification of the performance obligations in the contract This step describes how distinct performance obligations in the contract must be handled. ● Determination of the transaction price This step outlines what must be considered when establishing the transaction price, which is the amount the business expects to receive for transferring the goods and services to the customer. ● Allocation of the transaction price to the performance obligations in the contract This step outlines guidelines for allocating the transaction price across the contract’s separate performance obligations, and is what the customer agrees to pay for the goods and services. ● Recognition of revenue when, or as, the Company satisfies a performance obligation Revenue can be recognized as the business meets each performance obligation. This step specifies how that should happen. Contract Services The Company anticipates that the majority of revenues to be recognized in the near future will result from our fee for service partnership offering, designed for biopharmaceutical companies, as well as other organizations, of all sizes that have challenges analyzing data throughout the drug development process. The Company provides the customer with an analysis of large complex data sets using the Company’s proprietary Artificial Intelligence / Machine Learning platform called bfLEAP™. This platform is designed to predict targets of interest, patterns, relationships, and anomalies. The Company believes that there will be additional on-going work requested from partners therefore the service model utilizes a master services agreement with work or task orders issued for discrete analysis performed at the discovery, preclinical, or clinical stages of drug development. The Company receives a cash fee and in some instances the potential for rights to new intellectual property generated from the analysis. Once data analysis and the analysis report are complete, the Company delivers the analysis set to the customer and recognizes revenue at that point in time. Financial Instruments The carrying value of short-term instruments, including cash and cash equivalents, accounts payable and accrued expenses approximate fair value due to the relatively short period to maturity for these instruments. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a three-level valuation hierarchy for disclosures of fair value measurements, defined as follows: Level 1 - inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. Level 2 - inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments. Level 3 - inputs to the valuation methodology are unobservable and significant to the fair value. The Company does not have any assets or liabilities that are required to be measured and recorded at fair value on a recurring basis. Cash The Company considers cash to consist of cash on hand and temporary investments having an original maturity of 90 days or less that are readily convertible into cash. As of December 31, 2023 and 2022, cash balances were $ 2,624,730 57,670 Concentrations of Credit Risk The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Occasionally, the Company’s cash in interest-bearing accounts may exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management. Cost of Sales Cost of sales is comprised of royalties and the cost of outsourced services provided to the Company related to customer service contracts. Property and Equipment Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives. Advertising The Company follows the policy of charging the costs of advertising to expense as incurred. Income Taxes Deferred income tax assets and liabilities are determined based on the estimated future tax effects of net operating loss and credit carry forwards and temporary differences between the tax basis of assets and liabilities and their respective financial reporting amounts measured at the current enacted tax rates. The Company records an estimated valuation allowance on its deferred income tax assets if it is not more likely than not that these deferred income tax assets will be realized. The Company recognizes a tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained on examination by taxing authorities. Interest and penalties associated with such uncertain tax positions are classified as a component of income tax expense. Stock-Based Compensation Employee and non-employee share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period. Net Loss per Share We calculate basic net loss per share by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed by giving effect to all potentially dilutive common stock equivalents in the period, including unvested stock options and warrants. As we have reported losses for all periods presented, all potentially dilutive securities have been excluded from the calculation of diluted net loss per share as their effect would be antidilutive. Recent Accounting Pronouncements In December 2023, the FASB issued ASU No. 2024-09: Income Taxes (Topic 740): Improvements to Income Tax Disclosures that requires entities to disclose additional information about federal, state, and foreign income taxes primarily related to the income tax rate reconciliation and income taxes paid. The new standard also eliminates certain existing disclosure requirements related to uncertain tax positions and unrecognized deferred tax liabilities. The guidance is effective for our fiscal year ending December 31, 2025. The guidance does not affect recognition or measurement in our consolidated financial statements. The Company does not believe that any other recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying financial statements.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment	3. Property and Equipment Property and equipment consisted of $ 8,744 2,770 1,045 Depreciation expense totaled $ 1,725 1,045

Convertible Notes

Convertible Notes	12 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
Convertible Notes	4. Convertible Notes March 2020 Note On March 27, 2020, the Company entered into a convertible loan agreement with the Maryland Technology Development Corporation with a principal balance of $ 200,000 6 September 27, 2021 226,138 205,984 5,000,000 August 2021 Note In August 2021, the Company entered into a convertible loan agreement with an unrelated party for a commitment of up to $ 195,000 5 9 February 9, 2022 72,000 123,000 20 As of December 31, 2022, the loan was outstanding with a principal balance of $ 195,000 35,078 In connection with the convertible loan agreement, the Company also issued 195,000 1.00 five years 225,000 2.50 December 2021 Note On December 20, 2021, the Company entered into a loan agreement with an unrelated party. The loan provided for a December 19, 2022 10 6 25,000 The note was automatically convertible into shares of common stock at a discount to the IPO price or based on the valuation of the Company, whichever was more favorable to the holder. Initially, the loan was estimated to be issued with 355,114 1 Concurrent with the closing of the Company’s IPO, the note converted according to its terms into 6,939 Convertible Bridge Notes On April 11, 2022, the Company entered into an Exclusive placement agent and/or underwriter agreement with WallachBeth Capital LLC in connection with a proposed private and/or public offerings by the Company. On April 28, 2022, the Company received approximately $ 775,000 91,000 10 100,000 25,000 10 The Convertible Bridge Notes were initially convertible at the IPO at a 20 October 31, 2022 In connection with the Convertible Bridge Notes, the purchasers were also entitled to conditional warrants to be issued upon completion of the Company’s IPO. The agreement provided for the warrants to be exercisable for a period of five years from issuance at an exercise price equal to 110% of the IPO price or, if the Company failed to complete the IPO before October 22, 2022, 90% of the IPO price In the fourth quarter of 2022, the Company amended the Convertible Bridge Notes to (a) extend the maturity date until December 31, 2022, (b) provide that the conversion right would include interest through November 30, 2022, with interest accruing beyond that date being paid in cash and (c) revise the conversion price to be $ 4.27 Concurrent with the closing of the Company’s IPO in February 2023, all of the Convertible Bridge Notes converted according to their terms into 269,513

Convertible Notes _ Related Par

Convertible Notes – Related Party	12 Months Ended
	Dec. 31, 2023
Convertible Notes Related Party
Convertible Notes – Related Party	5. Convertible Notes – Related Party SAFE Agreement On July 8, 2021, the Company entered into a Simple Agreement for Future Equity (SAFE), with a related party, at a purchase price of $ 150,000 In February 2023, the SAFE terminated and converted into 32,967 63,626 As of December 31, 2022, the $ 150,000 6 August 2021 Note On August 19, 2021, the Company entered into a convertible loan agreement with a related party, with a principal balance of $ 99,900 5 9 In February 2023, the related party elected to convert the convertible loan into 21,747 29,333 In connection with the convertible loan agreement, the Company also issued 99,000 1.00 115,185 2.50

Related Party

Related Party	12 Months Ended
	Dec. 31, 2023
Related Party Transactions [Abstract]
Related Party	6. Related Party During the year ended December 31, 2023, the Company issued 75,000 During the year ended December 31, 2021, the Company issued 29,286 10 vest over different periods for up to 24 months 1,707 1,803 At various times in 2021, the Company entered into unsecured short term loan agreements with a related party for an aggregate principal balance of $ 49,000 5 1

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
Notes Payable	7 . Notes Payable In January 2023 the Company entered into a short-term note payable with a principal balance of $ 100,000 20 9 In February 2023, the Company entered into an agreement to finance a portion of the premium for its Directors and Officers Insurance. The agreement provides for financing of $ 697,534 repayments in 10 equal monthly installments 71,485 6.5

Stockholders_ Equity

Stockholders’ Equity	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
Stockholders’ Equity	8. Stockholders’ Equity Preferred Stock The Company has 10,000,000 0.00001 5,500,000 734,492 73,449 10 4.99 315,000 Common Stock The Company has 100,000,000 0.00001 ● Exchanged 734,429 ● Issued 205,984 226,138 ● Cancelled 112,225 ● Issued 39,879 After the Company signed two licenses for two drug programs from universities in the first half of 2022 it engaged an independent valuation firm to perform an Enterprise-Equity valuation. The results of this engagement resulted in an increase in the value per share of common stock used in the Black Scholes option pricing model employed to value the Company’s equity grants and warrant issuances. In February 2023, the Company completed its IPO for the sale of 1,297,318 6.50 8.4 7.80 8.125 In connection with the completion of its IPO, the Company issued an aggregate of 331,166 In connection with the IPO, in February 2023, the Company completed a 1-for-7 reverse split of our common stock. In February 2023, the Company issued 7,692 50,000 In the second quarter of 2023, we issued 436,533 436,533 1,494,658 Dilutive securities are excluded from the diluted earnings per share calculation because their effect is anti-dilutive. As of December 31, 2023 and December 31, 2022, 3,521,880 927,373 527,717 69,217 2022 Equity Incentive Plan In November 2022, the Company’s Board of Directors adopted, and its shareholders approved the 2022 Equity Incentive Plan (the “Plan”). The Plan provides for the granting of equity-based awards to employees, directors, and consultants. The Plan provides for equity-based awards including incentive stock options, non-qualified stock options, stock appreciation rights, performance share awards, cash awards and other equity-based awards. Awards are limited to a maximum term of 10 900,000 15 441,500 Stock Options The following tables summarizes the stock option activity for the years ended December 31, 2023 and 2022: Schedule of Stock Options Activity Number of Shares Weighted-Average Exercise Price Weighted-Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding at December 31, 2021 468,571 $ 3.32 7.4 $ - Granted - $ - Exercised - $ - Forfeited / canceled (399,354 ) $ - Outstanding at December 31, 2022 69,217 $ 3.06 7.1 $ - Granted 458,500 $ 4.34 Exercised - $ - Forfeited / canceled - $ - Outstanding at December 31, 2023 527,717 $ 4.17 9.0 $ 112,141 Vested at December 31, 2023 255,826 $ 4.01 8.5 $ 62,193 The fair value of options granted in the year ended December 31, 2023 was estimated using the Black-Scholes option pricing model based on the assumptions in the table below: Schedule of Options Valuation Assumptions 2023 Expected dividend yield 0% Expected volatility 87 92 Risk-free interest rate 3.4 4.4 Expected life (in years) 5.0 6.0 ● Volatility - ● Expected life of options – ● Risk-free interest rate – ● Dividend yield – The weighted-average grant-date fair value of options granted during the year ended December 31, 2023 was $ 3.15 1,445,200 585,500 No During the years ended December 31, 2023 and 2022, the Company recognized $ 592,268 2,010 As of December 31, 2023, the total unrecognized compensation expense related to unvested stock options, was approximately $ 861,000 1.9 Warrants During the years ended December 31, 2023 and 2022, the Company granted a total of 3,195,906 415,247 ten years vest over varying periods up to 24 months from the grant date 27,867 39,265 350,908 337,269 51,941 11,097 42,057 1,883 During the year ended December 31, 2021, the Company granted a total of 431,659 200,000 12,462 five years 0 200,000 During the year ended December 31, 2021, the Company issued 92,859 12,980 five years 50,735 11,097 99,000 115,185 2.50 1.00 15,412 195,000 225,000 2.50 64,978 The 92,859 During the year ended December 31, 2023, the Company issued the following warrants: ● In February 2023, in connection with the completion of the initial public offering, the Company issued 276,452 4.27 5 ● In February 2023, in connection with the completion of the initial public offering, the Company issued 18,000 8.125 4 ● As part of the sale of units in the Company’s initial public offering the Company issued 1,297,318 7.80 5 1,297,318 8.125 5 ● In February 2023, as part of the Company’s initial public offering, the Company issued 153,409 7.80 5 153,409 8.125 5 The following table provides details over the Company’s outstanding warrants including those issued as consideration for services and those issued in conjunction with transactions as of December 31, 2023: Schedule of Outstanding Warrants Exercise Price Expiration Number of Warrants $0.0007 2030 274,286 $2.10 $2.66 2026 2032 460,445 $3.36 $4.27 2028 2029 115,277 $6.51 $7.80 2026 2032 1,484,929 $8.125 2027 2028 1,461,227 3,796,164 During the years ended December 31, 2023 and 2022, the Company recognized $ 39,265 338,142 Warrants Issued as Consideration for Services The following table summarizes the activity for warrants issued as consideration for services for the years ended December 31, 2023 and 2022: Schedule of Warrant Activity Number of Warrants Weighted-Average Exercise Price Weighted-Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding at December 31, 2021 885,373 $ 2.59 7.4 $ 2,147 Granted 56,629 $ 3.87 Exercised - $ - Forfeited / canceled (263,826 ) $ 5.50 Outstanding at December 31, 2022 678,176 $ 1.57 7.6 $ 2,131,123 Granted - $ - Exercised - $ - Forfeited / canceled - $ - Outstanding at December 31, 2023 678,176 $ 1.57 6.6 $ 1,209,136 Vested at December 31, 2023 671,789 $ 1.56 6.6 $ 1,205,305 The fair value of options granted in the years ended 2022 were estimated using the Black-Scholes option pricing model based on the assumptions in the table below: Schedule of Warrants Valuation Assumptions 2022 Expected dividend yield 0 Expected volatility 89 Risk-free interest rate 1.86 1.97 Expected life (in years) 10 ● Volatility - ● Expected life of options – ● Risk-free interest rate – ● Dividend yield – No warrants were issued in the year ended December 31, 2023. As of December 31, 2023, the total unrecognized compensation expense related to unvested warrants was approximately $ 3,000 0.2 The total grant-date fair value of warrants vested during the year ended December 31, 2023 was approximately $ 39,300

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	9. Income Taxes Deferred income taxes reflect the net tax effects of loss and credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets for federal and state income taxes are as follows: Schedule of Deferred Tax Assets And Liabilities 2023 2022 December 31, 2023 2022 Deferred tax assets: Net operating losses $ 1,432,634 $ 924,000 Capitalized research and development 283,353 - Stock-based compensation 175,213 - Intangibles 173,273 - Other 9,438 - Total deferred tax assets 2,073,911 924,000 Valuation allowance (2,073,459 ) (924,000 ) Net deferred tax asset 452 - Deferred tax liabilities: Property and equipment (452 ) - Total deferred tax liabilities (452 ) - Net deferred tax asset / (liability) $ - $ - Realization of our deferred tax assets is dependent upon future earnings, if any, the timing, and amount of which are uncertain. Because of our lack of U.S. earnings history, the net U.S. deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by $1,151,827 585,000 As of December 31, 2023, the Company has available for federal income tax purposes a net operating loss carry forward of approximately $ 6.1 2 The Company has provided a valuation reserve against the full amount of the net operating loss benefit, since in the opinion of management, based upon the earnings history of the Company; it is more likely than not that the benefits will not be realized. All or portion of the remaining valuation allowance may be reduced in future years based on an assessment of earnings sufficient to fully utilize these potential tax benefits. We have incurred net operating losses since inception and we do not have any significant unrecognized tax benefits. Our policy is to include interest and penalties related to unrecognized tax benefits, if any, within the provision for taxes in the consolidated statements of operations. If we are eventually able to recognize our uncertain positions, our effective tax rate would be reduced. We currently have a full valuation allowance against out net deferred tax asset which would impact the timing of the effective tax rate benefit should any of these uncertain tax positions be favorably settled in the future. Any adjustments to our uncertain tax positions would result in an adjustment of our net operating loss or tax credit carry forwards rather than resulting in a cash outlay. We file income tax returns in the U.S. and certain state jurisdictions. We are not currently under examination in these jurisdictions for any tax year. The Company’s tax years beginning with 2020 are open tax years. Because of net operating losses and research credit carryovers, substantially all of our tax years remain open to examination. The Company did not have unrecognized tax benefits as of December 31, 2023 and 2022, and does not anticipate this to change significantly over the next 12 months. The Company will recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Reconciliations between the statutory federal income tax rate and the effective income tax rate of income tax expense is as follows: Effective Income Tax Rate of Income Tax Expense December 31, 2023 U.S. Federal statutory tax rate 21.0 % Stock-based compensation (1.1 ) Other (3.3 ) Change in valuation allowance (16.6 ) Total - %

Material Agreements

Material Agreements	12 Months Ended
	Dec. 31, 2023
Material Agreements
Material Agreements	10. Material Agreements JHU-APL Technology License On February 7, 2018, the Company entered into an exclusive, world-wide, royalty-bearing license from JHU-APL for the technology. The license covers three (3) issued patents, one (1) new provisional patent application, non-patent rights to proprietary libraries of algorithms and other trade secrets, the license also includes modifications and improvements. In October of 2021, the Company executed an amendment to the original license which represents improvements and new advanced analytics capabilities. In consideration of the rights granted to the Company under the License Agreement JHU received a warrant equal to five percent ( 5 8 50 1,500 20,000 80,000 300,000 39,879 8 3 50 25 30,000 60,000 300,000 On May 31, 2023, the Company and JHU-APL entered into Amendment number 1 of the July 8, 2022 License Agreement whereby the Company gained access to certain improvements including additional patents and knowhow in exchange for a series of payments totaling $ 275,000 75,000 $75,000 75,000 50,000 60,000 60,000 George Washington University - Beta2-spectrin siRNA License On January 14, 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from George Washington University (GWU) for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma (HCC). The license covers methods claimed in three US and worldwide patent applications, and also includes use of this approach for treatment of obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. In consideration of the rights granted to the Company under the License Agreement the Company paid GWU a $ 20,000 3 no Johns Hopkins University – Mebendazole License On February 22, 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from Johns Hopkins University (JHU) for the use of an improved formulation of Mebendazole for the treatment of any human cancer or neoplastic disease. This formulation shows potent activity in animal models of different types of cancer and has been evaluated in a Phase I clinical trial in patients with high-grade glioma (NCT01729260). The trial, an open-label dose-escalation study, assessed the safety and efficacy of the improved formulation with adjuvant temozolomide in 24 patients with newly diagnosed gliomas. Investigators observed no dose-limiting toxicity in patients receiving all but the highest tested dose (200mg/kg/day). Four of the 15 patients receiving the maximum tested dose of 200mg/kg/day experienced dose-limiting toxicity, all of which were reversed by decreasing or eliminating the dose given. There were no serious adverse events attributed to Mebendazole at any dose during the trial. 41.7% of patients who received Mebendazole were alive at two years after enrollment, and 25% were alive at four years (Gallia et al., 2021). The license covers six (6) issued patents and one (1) pending application. In consideration of the rights granted to the Company under the License Agreement, JHU will receive a staggered Upfront License Fee of $ 250,000 50,000 200,000 3.5 $5,000 10,000 20,000 30,000 50,000 250,000 10,000 242,671 Johns Hopkins University – Prodrug License On October 13, 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from JHU and the Institute of Organic Chemistry and Biochemistry (IOCB) of the Czech Academy of Sciences for rights to commercialize N-substituted prodrugs of Mebendazole that demonstrate improved solubility and bioavailability. The license covers prodrug compositions and use for treating disease as claimed in multiple US and worldwide patent applications. In consideration for the rights granted to the Company under the License Agreement JHU and IOCB will receive a staggered upfront license fee of $ 100,000 4.0 5,000 10,000 20,000 30,000 50,000 150,000 0 133,238

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies While not assured, management does not believe, based upon information available at this time, that a loss contingency will have a material adverse effect on the Company’s financial position, results of operations or cash flows. Additionally, the Company does not have any material commitments.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	12. Subsequent Events On February 5, 2024 the Company received net proceeds of approximately $ 4.9 1,507,139 1,507,139 3.782 5 4.16 218,382 750,000

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements include the accounts of Bullfrog AI Holdings, Inc. and our wholly owned subsidiaries and have been prepared in conformity with United States generally accepted accounting principles (“GAAP”). All intercompany accounts and transactions have been eliminated in consolidation. On February 13, 2023, we completed a 1-for-7 reverse split of our common stock
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. These estimates include, but are not limited to, revenue recognition, allowances for doubtful accounts, recoverability of deferred tax assets and certain other of our accrued liabilities. Actual results could differ from these estimates.
Revenue Recognition	Revenue Recognition The Company recognizes revenue based on the following five step model: ● Identification of the contract with a customer This step outlines the criteria that must be met when establishing a contract with a customer to supply goods or services. ● Identification of the performance obligations in the contract This step describes how distinct performance obligations in the contract must be handled. ● Determination of the transaction price This step outlines what must be considered when establishing the transaction price, which is the amount the business expects to receive for transferring the goods and services to the customer. ● Allocation of the transaction price to the performance obligations in the contract This step outlines guidelines for allocating the transaction price across the contract’s separate performance obligations, and is what the customer agrees to pay for the goods and services. ● Recognition of revenue when, or as, the Company satisfies a performance obligation Revenue can be recognized as the business meets each performance obligation. This step specifies how that should happen. Contract Services The Company anticipates that the majority of revenues to be recognized in the near future will result from our fee for service partnership offering, designed for biopharmaceutical companies, as well as other organizations, of all sizes that have challenges analyzing data throughout the drug development process. The Company provides the customer with an analysis of large complex data sets using the Company’s proprietary Artificial Intelligence / Machine Learning platform called bfLEAP™. This platform is designed to predict targets of interest, patterns, relationships, and anomalies. The Company believes that there will be additional on-going work requested from partners therefore the service model utilizes a master services agreement with work or task orders issued for discrete analysis performed at the discovery, preclinical, or clinical stages of drug development. The Company receives a cash fee and in some instances the potential for rights to new intellectual property generated from the analysis. Once data analysis and the analysis report are complete, the Company delivers the analysis set to the customer and recognizes revenue at that point in time.
Financial Instruments	Financial Instruments The carrying value of short-term instruments, including cash and cash equivalents, accounts payable and accrued expenses approximate fair value due to the relatively short period to maturity for these instruments. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a three-level valuation hierarchy for disclosures of fair value measurements, defined as follows: Level 1 - inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. Level 2 - inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments. Level 3 - inputs to the valuation methodology are unobservable and significant to the fair value. The Company does not have any assets or liabilities that are required to be measured and recorded at fair value on a recurring basis.
Cash	Cash The Company considers cash to consist of cash on hand and temporary investments having an original maturity of 90 days or less that are readily convertible into cash. As of December 31, 2023 and 2022, cash balances were $ 2,624,730 57,670
Concentrations of Credit Risk	Concentrations of Credit Risk The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Occasionally, the Company’s cash in interest-bearing accounts may exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management.
Cost of Sales	Cost of Sales Cost of sales is comprised of royalties and the cost of outsourced services provided to the Company related to customer service contracts.
Property and Equipment	Property and Equipment Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives.
Advertising	Advertising The Company follows the policy of charging the costs of advertising to expense as incurred.
Income Taxes	Income Taxes Deferred income tax assets and liabilities are determined based on the estimated future tax effects of net operating loss and credit carry forwards and temporary differences between the tax basis of assets and liabilities and their respective financial reporting amounts measured at the current enacted tax rates. The Company records an estimated valuation allowance on its deferred income tax assets if it is not more likely than not that these deferred income tax assets will be realized. The Company recognizes a tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained on examination by taxing authorities. Interest and penalties associated with such uncertain tax positions are classified as a component of income tax expense.
Stock-Based Compensation	Stock-Based Compensation Employee and non-employee share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period.
Net Loss per Share	Net Loss per Share We calculate basic net loss per share by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed by giving effect to all potentially dilutive common stock equivalents in the period, including unvested stock options and warrants. As we have reported losses for all periods presented, all potentially dilutive securities have been excluded from the calculation of diluted net loss per share as their effect would be antidilutive.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In December 2023, the FASB issued ASU No. 2024-09: Income Taxes (Topic 740): Improvements to Income Tax Disclosures that requires entities to disclose additional information about federal, state, and foreign income taxes primarily related to the income tax rate reconciliation and income taxes paid. The new standard also eliminates certain existing disclosure requirements related to uncertain tax positions and unrecognized deferred tax liabilities. The guidance is effective for our fiscal year ending December 31, 2025. The guidance does not affect recognition or measurement in our consolidated financial statements. The Company does not believe that any other recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying financial statements.

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
Schedule of Stock Options Activity	The following tables summarizes the stock option activity for the years ended December 31, 2023 and 2022: Schedule of Stock Options Activity Number of Shares Weighted-Average Exercise Price Weighted-Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding at December 31, 2021 468,571 $ 3.32 7.4 $ - Granted - $ - Exercised - $ - Forfeited / canceled (399,354 ) $ - Outstanding at December 31, 2022 69,217 $ 3.06 7.1 $ - Granted 458,500 $ 4.34 Exercised - $ - Forfeited / canceled - $ - Outstanding at December 31, 2023 527,717 $ 4.17 9.0 $ 112,141 Vested at December 31, 2023 255,826 $ 4.01 8.5 $ 62,193
Schedule of Options Valuation Assumptions	The fair value of options granted in the year ended December 31, 2023 was estimated using the Black-Scholes option pricing model based on the assumptions in the table below: Schedule of Options Valuation Assumptions 2023 Expected dividend yield 0% Expected volatility 87 92 Risk-free interest rate 3.4 4.4 Expected life (in years) 5.0 6.0
Schedule of Outstanding Warrants	The following table provides details over the Company’s outstanding warrants including those issued as consideration for services and those issued in conjunction with transactions as of December 31, 2023: Schedule of Outstanding Warrants Exercise Price Expiration Number of Warrants $0.0007 2030 274,286 $2.10 $2.66 2026 2032 460,445 $3.36 $4.27 2028 2029 115,277 $6.51 $7.80 2026 2032 1,484,929 $8.125 2027 2028 1,461,227 3,796,164
Schedule of Warrant Activity	The following table summarizes the activity for warrants issued as consideration for services for the years ended December 31, 2023 and 2022: Schedule of Warrant Activity Number of Warrants Weighted-Average Exercise Price Weighted-Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding at December 31, 2021 885,373 $ 2.59 7.4 $ 2,147 Granted 56,629 $ 3.87 Exercised - $ - Forfeited / canceled (263,826 ) $ 5.50 Outstanding at December 31, 2022 678,176 $ 1.57 7.6 $ 2,131,123 Granted - $ - Exercised - $ - Forfeited / canceled - $ - Outstanding at December 31, 2023 678,176 $ 1.57 6.6 $ 1,209,136 Vested at December 31, 2023 671,789 $ 1.56 6.6 $ 1,205,305
Schedule of Warrants Valuation Assumptions	The fair value of options granted in the years ended 2022 were estimated using the Black-Scholes option pricing model based on the assumptions in the table below: Schedule of Warrants Valuation Assumptions 2022 Expected dividend yield 0 Expected volatility 89 Risk-free interest rate 1.86 1.97 Expected life (in years) 10

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets And Liabilities	Schedule of Deferred Tax Assets And Liabilities 2023 2022 December 31, 2023 2022 Deferred tax assets: Net operating losses $ 1,432,634 $ 924,000 Capitalized research and development 283,353 - Stock-based compensation 175,213 - Intangibles 173,273 - Other 9,438 - Total deferred tax assets 2,073,911 924,000 Valuation allowance (2,073,459 ) (924,000 ) Net deferred tax asset 452 - Deferred tax liabilities: Property and equipment (452 ) - Total deferred tax liabilities (452 ) - Net deferred tax asset / (liability) $ - $ -
Effective Income Tax Rate of Income Tax Expense	Effective Income Tax Rate of Income Tax Expense December 31, 2023 U.S. Federal statutory tax rate 21.0 % Stock-based compensation (1.1 ) Other (3.3 ) Change in valuation allowance (16.6 ) Total - %

Organization and Nature of Bu_2

Organization and Nature of Business (Details Narrative) - Subsequent Event [Member] - USD ($)	Feb. 29, 2024	Feb. 21, 2024
Underwritten Public Offering [Member]
Subsequent Event [Line Items]
Net proceeds from share issuance	$ 4,900,000
Number of shares issued	1,507,139
Warrants to purhcase common stock	1,507,139
Offering price per share	$ 3.782
Warrants term	5 years
Exercise price of warrant	$ 4.16
Over-Allotment Option [Member]
Subsequent Event [Line Items]
Net proceeds from share issuance		$ 750,000
Number of shares issued		218,382

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	Feb. 13, 2023	Dec. 31, 2023	Dec. 31, 2022
Subsidiary, Sale of Stock [Line Items]
Cash balance		$ 2,624,730	$ 57,670
IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Reverse stock split	completed a 1-for-7 reverse split of our common stock

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Equiment	$ 8,744	$ 8,744
Accumulated depreciation	2,770	1,045
Depreciation expense	$ 1,725	$ 1,045

Convertible Notes (Details Narr

Convertible Notes (Details Narrative) - USD ($)

1 Months Ended

12 Months Ended

Feb. 28, 2023

Apr. 28, 2022

Dec. 20, 2021

Aug. 19, 2021

Mar. 27, 2020

Sep. 30, 2022

Apr. 30, 2022

Aug. 31, 2021

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Jan. 31, 2023

May 31, 2022

Short-Term Debt [Line Items]

Principal balance

$ 49,000

$ 100,000

Interest rate

5%

9%

Debt converted

$ 226,138

Shares issued in debt conversion

205,984

Proceeds from notes payable

$ 100,000

Convertible Bridge Notes And Warrants [Member]

Short-Term Debt [Line Items]

Original issuance discount rate

10%

Proceeds from notes payable

$ 775,000

Fees expense

91,000

Convertible Bridge Notes [Member]

Short-Term Debt [Line Items]

Maturity date

Oct. 31, 2022

Shares issued in debt conversion

269,513

Conversion discount rate

20%

Conversion price

$ 4.27

Warrant [Member]

Short-Term Debt [Line Items]

Warrant description

The agreement provided for the warrants to be exercisable for a period of five years from issuance at an exercise price equal to 110% of the IPO price or, if the Company failed to complete the IPO before October 22, 2022, 90% of the IPO price

Nonrelated Party [Member] | Convertible Bridge Notes And Warrants [Member]

Short-Term Debt [Line Items]

Original issuance discount rate

10%

Proceeds from notes payable

$ 25,000

Related Party [Member] | Convertible Bridge Notes And Warrants [Member]

Short-Term Debt [Line Items]

Sale of stock value

$ 100,000

Convertible Loan Agreement [Member] | Nonrelated Party [Member]

Short-Term Debt [Line Items]

Interest rate

9%

Maturity date

Feb. 09, 2022

Loan principal amount outstanding

$ 195,000

$ 195,000

Original issuance discount rate

5%

Proceeds from notes payable

123,000

$ 72,000

Conversion discount rate

20%

Accrued interest

$ 35,078

Warrants issued

195,000

225,000

Exercise price

$ 1

$ 2.50

Warrants term

5 years

Convertible Loan Agreement [Member] | Related Party [Member]

Short-Term Debt [Line Items]

Interest rate

9%

Shares issued in debt conversion

21,747

Loan principal amount outstanding

$ 99,900

Original issuance discount rate

5%

Warrants issued

99,000

Exercise price

$ 1

Loan Agreement [Member] | Nonrelated Party [Member]

Short-Term Debt [Line Items]

Interest rate

6%

Maturity date

Dec. 19, 2022

Shares issued in debt conversion

6,939

Original issuance discount rate

10%

Proceeds from notes payable

$ 25,000

$ 1,000,000

Warrants issued

355,114

Maryland Technology Development Corporation [Member] | Convertible Loan Agreement [Member]

Short-Term Debt [Line Items]

Principal balance

$ 200,000

Interest rate

6%

Maturity date

Sep. 27, 2021

Debt converted

$ 226,138

Shares issued in debt conversion

205,984

Fully diluted equity

$ 5,000,000

Convertible Notes _ Related P_2

Convertible Notes – Related Party (Details Narrative) - USD ($)			12 Months Ended
	Feb. 28, 2023	Aug. 19, 2021	Dec. 31, 2022	Jan. 31, 2023	May 31, 2022	Dec. 31, 2021	Jul. 08, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Conversion of stock, shares			205,984
Interest rate				9%		5%
Simple Agreement for Future Equity [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Convertible notes payable			$ 150,000
Conversion of stock, shares	32,967
Loss on conversion	$ 63,626
Interest rate			6%
Loss on conversion	$ (63,626)
Simple Agreement for Future Equity [Member] | Related Party [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Convertible notes payable							$ 150,000
Convertible Loan Agreement [Member] | Related Party [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Convertible notes payable		$ 99,900
Conversion of stock, shares	21,747
Loss on conversion	$ (29,333)
Interest rate		9%
Original issuance discount rate		5%
Loss on conversion	$ 29,333
Number of warrant shares	99,000
Warrant exercise price per share	$ 1
New Loan Agreement [Member] | Related Party [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of warrant shares					115,185
Warrant exercise price per share					$ 2.50

Related Party (Details Narrativ

Related Party (Details Narrative) - USD ($)	1 Months Ended		12 Months Ended
	Dec. 31, 2023	Dec. 31, 2021	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Jan. 31, 2023
Related Party Transaction [Line Items]
Stock-based compensation			$ 631,533	$ 340,152
Principal balance		$ 49,000			$ 49,000	$ 100,000
Interest rate		5%			5%	9%
Interest rate increase	6.50%	1%
Share-Based Payment Arrangement, Option [Member]
Related Party Transaction [Line Items]
Stock-based compensation			$ 1,707	$ 1,803
Share-Based Payment Arrangement, Option [Member] | Related Party [Member]
Related Party Transaction [Line Items]
Options issued for services					29,286
Original life					10 years
Options vesting description					vest over different periods for up to 24 months
Chief Financial Officer [Member] | Share-Based Payment Arrangement, Option [Member]
Related Party Transaction [Line Items]
Options issued for services			75,000

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	1 Months Ended
	Dec. 31, 2023	Feb. 28, 2023	Dec. 31, 2021	Jan. 31, 2023
Debt Disclosure [Abstract]
Principal balance			$ 49,000	$ 100,000
Discount rate			20%
Interest rate			5%	9%
Premium amount		$ 697,534
Debt term		repayments in 10 equal monthly installments
Installment amount	$ 71,485
Accrued interest	6.50%		1%

Schedule of Stock Options Activ

Schedule of Stock Options Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Equity [Abstract]
Number of Shares, Outstanding at Beginning	69,217	468,571
Weighted-Average Exercise Price, Outstanding at Beginning	$ 3.06	$ 3.32
Weighted-Average Remaining Contractual Term (Years), Outstanding	9 years	7 years 1 month 6 days	7 years 4 months 24 days
Aggregate Intrinsic Value, Outstanding at Beginning
Number of Shares, Granted	458,500
Weighted-Average Exercise Price, Granted	$ 4.34
Number of Shares, Exercised
Weighted-Average Exercise Price, Exercised
Number of Shares, Forfeited / canceled		(399,354)
Weighted-Average Exercise Price, Forfeited / canceled
Number of Shares, Outstanding at Ending	527,717	69,217	468,571
Weighted-Average Exercise Price, Outstanding at Ending	$ 4.17	$ 3.06	$ 3.32
Aggregate Intrinsic Value, Outstanding at Ending	$ 112,141
Number of Shares, Vested at Ending	255,826
Weighted-Average Exercise Price, Vested at Ending	$ 4.01
Weighted-Average Remaining Contractual Term (Years), Vested at Ending	8 years 6 months
Aggregate Intrinsic Value, Vested at Ending	$ 62,193

Schedule of Options Valuation A

Schedule of Options Valuation Assumptions (Details)	12 Months Ended
	Dec. 31, 2023
Expected dividend yield	0%
Expected volatility, minimum	87%
Expected volatility, maximum	92%
Risk-free interest rate, minimum	3.40%
Risk-free interest rate, maximum	4.40%
Minimum [Member]
Expected life (in years)	5 years
Maximum [Member]
Expected life (in years)	6 years

Schedule of Outstanding Warrant

Schedule of Outstanding Warrants (Details)	12 Months Ended
	Dec. 31, 2023 $ / shares shares
Class of Warrant or Right [Line Items]
Number of Warrants | shares	3,796,164
$0.0007 [Member]
Class of Warrant or Right [Line Items]
Exercise price of warrant	$ 0.0007
Expiration Period	2030
Number of Warrants | shares	274,286
$2.10 - $2.66 [Member]
Class of Warrant or Right [Line Items]
Number of Warrants | shares	460,445
$2.10 - $2.66 [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise price of warrant	$ 2.10
Expiration Period	2026
$2.10 - $2.66 [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise price of warrant	$ 2.66
Expiration Period	2032
$3.36 - $4.27 [Member]
Class of Warrant or Right [Line Items]
Number of Warrants | shares	115,277
$3.36 - $4.27 [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise price of warrant	$ 3.36
Expiration Period	2028
$3.36 - $4.27 [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise price of warrant	$ 4.27
Expiration Period	2029
6.51 - $7.80 [Member]
Class of Warrant or Right [Line Items]
Number of Warrants | shares	1,484,929
6.51 - $7.80 [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise price of warrant	$ 6.51
Expiration Period	2026
6.51 - $7.80 [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise price of warrant	$ 7.80
Expiration Period	2032
$8.125 [Member]
Class of Warrant or Right [Line Items]
Exercise price of warrant	$ 8.125
Number of Warrants | shares	1,461,227
$8.125 [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Expiration Period	2027
$8.125 [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Expiration Period	2028

Schedule of Warrant Activity (D

Schedule of Warrant Activity (Details) - USD ($)		3 Months Ended	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Warrants, Outstanding at Beginning			678,176	885,373
Weighted-Average Exercise Price, Outstanding at Beginning			$ 1.57	$ 2.59
Weighted-Average Remaining Contractual Term (Years), Outstanding			6 years 7 months 6 days	7 years 7 months 6 days	7 years 4 months 24 days
Aggregate Intrinsic Value, Outstanding at Beginning			$ 2,131,123	$ 2,147
Number of Warrants, Granted				56,629
Weighted-Average Exercise Price, Granted				$ 3.87
Number of Warrants, Exercised
Weighted-Average Exercise Price, Exercised
Number of Warrants, Forfeited / Canceled				(263,826)
Weighted-Average Exercise Price, Forfeited / canceled				$ 5.50
Number of Warrants, Outstanding at Ending			678,176	678,176	885,373
Weighted-Average Exercise Price, Outstanding at Ending			$ 1.57	$ 1.57	$ 2.59
Aggregate Intrinsic Value, Outstanding at Ending			$ 1,209,136	$ 2,131,123	$ 2,147
Number of Warrants, Vested at Ending			671,789
Weighted-Average Remaining Contractual Term (Years), Vested			6 years 7 months 6 days
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Warrants, Granted			3,195,906	415,247	431,659
Number of Warrants, Exercised		(436,533)
Number of Warrants, Forfeited / Canceled	(200,000)
Weighted-Average Exercise Price, Vested at Ending			$ 1.56
Aggregate Intrinsic Value, Vested at Ending					$ 1,205,305

Schedule of Warrants Valuation

Schedule of Warrants Valuation Assumptions (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expected dividend yield	0%
Risk free interest rate, minimum	3.40%
Risk free interest rate, maximum	4.40%
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expected dividend yield		0%
Expected volatility		89%
Risk free interest rate, minimum		1.86%
Risk free interest rate, maximum		1.97%
Expeced life (in years)		10 years

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)				1 Months Ended		3 Months Ended	12 Months Ended
	Feb. 13, 2023	Oct. 05, 2022	Jun. 30, 2022	Feb. 28, 2023	Nov. 30, 2022	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	May 31, 2022
Class of Stock [Line Items]
Preferred stock, shares authorized							10,000,000
Preferred stock, par value							$ 0.00001
Preferred stock value							$ 1	$ 1
Common stock, shares authorized							100,000,000	100,000,000
Common stock, par or stated value per share							$ 0.00001	$ 0.00001
Shares issued in conversion of debt								205,984
Conversion of convertible notes value								$ 226,138
Shares, issued for services				7,692
Value, issued for services				$ 50,000			$ 50,000
Shares issued in exercise of warrant						436,533
Warrant exercised
Proceeds from exercise of warrant						$ 1,494,658	$ 1,494,658
Weighted-average grant-date fair value of options granted							$ 3.15
Number of options, exercised
Compensation expense related to stock options							$ 592,268	$ 2,010
Unrecognized compensation expense							$ 861,000
Weighted average period term							1 year 10 months 24 days
Share based compensation granted								56,629
Warrants reclassified fair value								$ 11,097
Warrant cancelled								263,826
Warrant shares									92,859
Equity Option [Member]
Class of Stock [Line Items]
Fair value of warrants							$ 1,445,200	$ 585,500
2022 Equity Incentive Plan [Member]
Class of Stock [Line Items]
Original life					10 years
Award authorized but unissued							441,500
Increased payment award, percentage					15%
Warrant [Member]
Class of Stock [Line Items]
Antidilutive securities							3,521,880	927,373
Tradeable Warrants [Member]
Class of Stock [Line Items]
Exercise price of warrant				$ 7.80
Non Tradeable Warrants [Member]
Class of Stock [Line Items]
Exercise price of warrant				$ 8.125
IPO [Member]
Class of Stock [Line Items]
Shares issued in conversion of debt				331,166
Sale of shares				1,297,318
Issue price per share				$ 6.50
Gross proceeds				$ 8,400,000
Reverse stock split	completed a 1-for-7 reverse split of our common stock
Maximum [Member] | 2022 Equity Incentive Plan [Member]
Class of Stock [Line Items]
Award authorized but unissued					900,000
Exchange Agreement [Member] | Investors [Member] | Minimum [Member]
Class of Stock [Line Items]
Equity method investment, ownership percentage		4.99%
Prior Agreements and New Agreements [Member]
Class of Stock [Line Items]
Shares cancelled								112,225
Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued							1,297,318
Shares, issued for services							7,692
Value, issued for services							$ 1
Shares issued in exercise of warrant							436,533	39,879
Antidilutive securities							527,717	69,217
Common Stock [Member] | IPO [Member]
Class of Stock [Line Items]
Reverse stock split				completed a 1-for-7 reverse split of our common stock.
Common Stock [Member] | Exchange Agreement [Member] | Investor [Member]
Class of Stock [Line Items]
Conversion of convertible securities, shares		734,492
Common Stock [Member] | License Agreement [Member]
Class of Stock [Line Items]
Number of shares issued								39,879
Warrant [Member]
Class of Stock [Line Items]
Exercise price of warrant										$ 1
Warrant exercised						436,533
Original life							10 years
Fair value of warrants							$ 39,300
Share based compensation granted							3,195,906	415,247	431,659
Vesting description							vest over varying periods up to 24 months from the grant date
Warrants shares vested							27,867		0
Intrinsic value							$ 39,265
Warrants shares vested								350,908
Fair value value of warrants vested								$ 337,269
Warrants to purhcase common stock								51,941
Warrants reclassified fair value								$ 11,097
Warrant shares, forfeited								42,057		99,000
Warrant shares, forfeited								$ 1,883
Expiration term									5 years
Warrant cancelled			200,000
Warrant unissued			50,735
Warrant unissued, fair value			$ 11,097
Compensation expense							$ 39,265	$ 338,142
Warrant [Member] | IPO [Member] | Debt Holders [Member]
Class of Stock [Line Items]
Exercise price of warrant				$ 4.27
Expiration term				5 years
Warrants issued				276,452
Warrant [Member] | IPO [Member] | Underwriters [Member]
Class of Stock [Line Items]
Exercise price of warrant				$ 8.125
Expiration term				4 years
Warrants issued				18,000
Warrant [Member] | Advisors [Member]
Class of Stock [Line Items]
Share based compensation granted									200,000
Fair value of warrants									$ 12,462
Warrant [Member] | Convertible Bridge Debt Agreements [Member]
Class of Stock [Line Items]
Warrants to purhcase common stock									92,859
Fair value of warrants									$ 12,980
Expiration term									5 years
Warrant [Member] | New Agreements [Member]
Class of Stock [Line Items]
Exercise price of warrant										$ 2.50
Warrants to purhcase common stock										115,185
Fair value of warrants										$ 15,412
Warrant One [Member]
Class of Stock [Line Items]
Warrant shares, forfeited										195,000
Warrant One [Member] | New Agreements [Member]
Class of Stock [Line Items]
Exercise price of warrant										$ 2.50
Warrants to purhcase common stock										225,000
Fair value of warrants										$ 64,978
Tradeable Warrants [Member] | IPO [Member]
Class of Stock [Line Items]
Exercise price of warrant				$ 7.80
Expiration term				5 years
Warrants issued				1,297,318
Tradeable Warrants [Member] | Over-Allotment Option [Member]
Class of Stock [Line Items]
Exercise price of warrant				$ 7.80
Expiration term				5 years
Warrants issued				153,409
Non Tradeable Warrants [Member] | IPO [Member]
Class of Stock [Line Items]
Exercise price of warrant				$ 8.125
Expiration term				5 years
Warrants issued				1,297,318
Non Tradeable Warrants [Member] | Over-Allotment Option [Member]
Class of Stock [Line Items]
Exercise price of warrant				$ 8.125
Expiration term				5 years
Warrants issued				153,409
Unvested Warrants [Member]
Class of Stock [Line Items]
Weighted average period term							2 months 12 days
Unrecognized compensation expense							$ 3,000
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized							5,500,000	5,500,000
Preferred stock, par value							$ 0.00001	$ 0.00001
Series A Convertible Preferred Stock [Member] | Exchange Agreement [Member] | Investor [Member]
Class of Stock [Line Items]
Conversion of convertible securities, shares		73,449
Common stock issuable on conversion		10
Series A Preferred Stock [Member] | Exchange Agreement [Member]
Class of Stock [Line Items]
Conversion of convertible securities, shares								734,429
Series A Preferred Stock [Member] | Exchange Agreement [Member] | Investor [Member]
Class of Stock [Line Items]
Preferred stock value		$ 315,000

Schedule of Deferred Tax Assets

Schedule of Deferred Tax Assets And Liabilities (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Net operating losses	$ 1,432,634	$ 924,000
Capitalized research and development	283,353
Stock-based compensation	175,213
Intangibles	173,273
Other	9,438
Total deferred tax assets	2,073,911	924,000
Valuation allowance	(2,073,459)	(924,000)
Net deferred tax asset	452
Property and equipment	(452)
Total deferred tax liabilities	(452)
Net deferred tax asset / (liability)

Effective Income Tax Rate of In

Effective Income Tax Rate of Income Tax Expense (Details)	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
U.S. Federal statuatory tax rate	21%
Stock-based compensation	(1.10%)
Other	(3.30%)
Change in valuation allowance	(16.60%)
Total

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Increase in valuation allowance	$ 1,151,827	$ 585,000
Operating loss carryforwards federal	6,100,000
Operating loss carryforwards state	$ 2,000,000

Material Agreements (Details Na

Material Agreements (Details Narrative) - USD ($)						1 Months Ended
	May 31, 2023	Feb. 28, 2023	Oct. 13, 2022	Jul. 08, 2022	Feb. 22, 2022	Oct. 31, 2021	Dec. 31, 2023	Dec. 31, 2022	Jan. 14, 2022
JHU - APL Technology License Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrant percent						5%
Royalty percent						8%
Percentage of sublicense						50%
Maintenance fee						$ 1,500
JHU - APL Technology License Agreement [Member] | 2022 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty payments						20,000
JHU - APL Technology License Agreement [Member] | 2023 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty payments						80,000
JHU - APL Technology License Agreement [Member] | 2024 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty payments						$ 300,000
New License Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty payments	$ 275,000
Common stock issued				39,879
Accrued royalty expenses							$ 0	$ 0
New License Agreement [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of sublicense				50%
New License Agreement [Member] | Minimum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sublicense fee based on revenue				25%
New License Agreement [Member] | Internally Development Drug Projects [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty percent				3%
New License Agreement [Member] | Other Parties [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty percent				8%
New License Agreement [Member] | 2022 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty payments	60,000			$ 30,000
New License Agreement [Member] | 2023 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty payments	75,000			60,000
Accrued royalty expenses							60,000
New License Agreement [Member] | 2024 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty payments				$ 300,000
New License Agreement [Member] | 2025 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty payments	75,000
New License Agreement [Member] | 2026 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty payments	75,000
New License Agreement [Member] | 2027 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty payments	$ 50,000
George Washington University - Beta2-spectrin siRNA License Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty percent									3%
Licence initiation fee									$ 20,000
Johns Hopkins University - Mebendazole License Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty percent					3.50%
Accrued royalty expenses							10,000	242,671
Upfront licence fee					$ 250,000
License fee initial payment		$ 200,000			50,000
Annual minimum royalty payment					250,000
Johns Hopkins University - Mebendazole License Agreement [Member] | 2023 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty payments					5,000
Johns Hopkins University - Mebendazole License Agreement [Member] | 2024 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty payments					10,000
Johns Hopkins University - Mebendazole License Agreement [Member] | 2025 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty payments					20,000
Johns Hopkins University - Mebendazole License Agreement [Member] | 2026 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty payments					30,000
Johns Hopkins University - Mebendazole License Agreement [Member] | 2027 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty payments					$ 50,000
Johns Hopkins University - Prodrug License Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty percent			4%
Upfront licence fee			$ 100,000
Annual minimum royalty payment			150,000
Johns Hopkins University - Prodrug License Agreement [Member] | 2027 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty payments			5,000
Johns Hopkins University - Prodrug License Agreement [Member] | 2028 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty payments			10,000
Johns Hopkins University - Prodrug License Agreement [Member] | 2029 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty payments			20,000
Johns Hopkins University - Prodrug License Agreement [Member] | 2030 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty payments			30,000
Johns Hopkins University - Prodrug License Agreement [Member] | 2031 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty payments			$ 50,000
License Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accrued expense							$ 0	$ 133,238

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Subsequent Event [Member] - USD ($)	Feb. 29, 2024	Feb. 21, 2024
Underwritten Public Offering [Member]
Subsequent Event [Line Items]
Net proceeds from share issuance	$ 4,900,000
Number of shares issued	1,507,139
Warrants to purhcase common stock	1,507,139
Offering price per share	$ 3.782
Warrants term	5 years
Exercise price of warrant	$ 4.16
Over-Allotment Option [Member]
Subsequent Event [Line Items]
Net proceeds from share issuance		$ 750,000
Number of shares issued		218,382